The Relation of Microtubule-Associated Protein 2 and Cell Migration

NCT ID: NCT00174109

Last Updated: 2005-09-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-08-31

Study Completion Date

2006-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Clarify the relation of microtubule-associated protein 2 and cell migration

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Betel quid chewing has been shown to have intimate correlation with oral cancer. In Taiwan, the incidence of oral cancer is the fourth most common malignancy in male and in fact, 90% of which has been linked to betel quid chewing. The predisposing factors in oral cancers between the western countries and India, Southeast Asia including Taiwan are different. The factor is smoking in the former countries and betel quid chewing is the most important one in the latter groups. The genetic aberrations of oral cancers are different too between the western countries and India, Southeast Asia including Taiwan. The percentage of RAS mutations of oral cancers in the western countries is around 5%, and 35% in the India. In Taiwan, the RAS mutation rate revealed with immunohistochemical staining is 92%, comparing with those in western countries (62%), Japan (55-65%) and vice versa in the p53 mutations. The percentage of p53 mutations of oral cancers in the western countries is around 50%, and 16% in the India, Southeast Asia and Taiwan. It is generally believed that betel nut itself, arecoline and arecaidine, the major betel alkaloids, account for the etiological factors in the pathogenesis of oral cancer while betel quid supplements, unlike the former two main components, were reported to have little relevancy to oral cancer. Despite the fact that the cytotoxic and genotoxic effects of betel nut extract and arecoline, arecaidine have been extensively documented, and that some well-studied oncogenes or tumor suppressor genes have been implicated in betel quid-related oral cancer, the molecular mechanisms, addressed in a broader view, by which betel nut ingredients lead to oral tumorigenesis are not fully understood. Our preliminary results, by virtue of different genome-wide screening approaches to explore cellular functions of protein kinases in this context, identified several candidates that showed differential expression upon treatment of BQ on primary cultures from human oral mucosa. Of the candidates isolated, microtubule-associated protein 2 (MAP2), a neuron-specific cytoskeletal protein that is thought to predominantly express in rat brain cells, was found up-regulated at RNA level by RT-PCR in primary cultures. Our expanded immunohistochemical results of normal mucosa, leukoplakia and oral squamous cell carcinoma (OSCC) suggest that expression of the MAP2 significantly correlates with progression of BQ-induced OSCC (P = 0.0046), since the percentage of MAP2 positive staining is as much fourfold in BQ-exposed OSCC (41.2%) as in BQ-free OSCC (10.5%), whereas normal mucosa and leukoplakia show much less immunoreactivity as a whole. Furthermore, the MAP2 is shown to be preferentially expressed in histopathologically less differentiated OSCC (P = 0.014). Finally, we show that the MAP2 is highly expressed in the majority of invasive OSCC (67%). Consequently, this finding, in conjunction with the previous one, raise a possibility that overexpression of the MAP2 may play a critical role in the development of highly malignant OSCC characteristic of invasive and/or metastatic. Here we study the issue by establishing an in vitro system where extracts from the whole betel quid sandwiches are used to treat head and neck cancer cell lines and primary oral epithelial cells and subsequently, the effects of such treatments will be evaluated in terms of cell migration, Western blotting. Eight head and neck cancer cell lines and normal oral mucosae from 8 patients undergoing oral surgery will be collected. Extracts from the whole betel quid sandwiches with the concentration of 1.5 mg/ml will be added to the cell lines and primary oral epithelial cells for 1,3 and 5 days, respectively. Migration assay and detection of MAP2 expression will be performed to elucidate the relationship of MAP2 and cell migration.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Oral Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

arecoline, oral cancer, MAP2, cell migration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

NATURAL_HISTORY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* oral cancer

Exclusion Criteria

* nil
Minimum Eligible Age

30 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Taiwan University Hospital

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jenq-Yuh Ko, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

National Taiwan University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Taiwan University Hospital

Taipei, , Taiwan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jenq-Yuh Ko, MD, PhD

Role: CONTACT

Phone: 886-2-23123456

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jenq-Yuh Ko, MD, PhD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

9461700625

Identifier Type: -

Identifier Source: org_study_id